Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500701 | 0.81 | HTT (0.64) | — | |
| SCHEMBL29767521 | 0.81 | APP (0.42) | DHFR | |
| SCHEMBL30376225 | 0.81 | HTT (0.64) | — | |
| Quinazoline-2,4,6-Triamine SCHEMBL335027 | 0.79 | DCPS (0.57) | DCPSDHFR | |
| Quinazoline-2,4,6-Triamine SCHEMBL30050079 | 0.79 | DCPS (0.57) | DCPSDHFR | |
| SCHEMBL27556561 | 0.77 | CYP1A1 (0.69) | — | |
| SCHEMBL4358438 | 0.76 | HTT (0.68) | DCPSDHFR | |
| SCHEMBL29649743 | 0.76 | HTT (0.68) | DCPSDHFR | |
| SCHEMBL4755412 | 0.76 | DCPS (0.53) | DCPSDHFR | |
| SCHEMBL6679745 | 0.76 | HRH4 (0.58) | DCPSDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256197-B2 | Methods for synthesis of diarylmethanes | DANA-FARBER CANCER INSTITUTE (US) | 2007-08-14 | — | — | US | disclosed |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DANA-FARBER CANCER INSTITUTE | 2004-12-30 | — | — | US | disclosed |
| US-20040092515-A1 | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | MELACURE THERAPEUTICS AB (SE) | 2004-05-13 | — | — | US | disclosed |
| EP-1366028-A1 | DIAMINOQUINAZOLINE ESTERS FOR USE AS DIHYDROFOLATE REDUCTASE INHIBITORS | Melacure Therapeutics AB (SE) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003031458-A1 | METHODS FOR SYNTHESIS OF DIARYLMETHANES | DANA-FARBER CANCER INSTITUTE (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002068397-A1 | DIAMINOQUINAZOLINE ESTERS FOR USE AS DIHYDROFOLATE REDUCTADE INHIBITORS | MELACURE THERAPEUTICS AB (SE) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092515-A1 | Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors | DHFR, DPYD, DHODH | DCPS 671/4885DHFR 1/4885 |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DHFR, DPYD, DHODH | DCPS 778/4885DHFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.